Get in
touch

Feedback plc

Information for investors, shareholders and analysts about Feedback plc

Feedback plc (AIM: FDBK) provides innovative software and systems through our trading subsidiary, Feedback Medical.

We liberate the data and knowledge from multiple healthcare IT systems and deliver better workflow to enable clinicians to communicate, collaborate and provide the best healthcare for their patients. We connect care settings with diagnostic and other relevant data to drive better, faster, safer decision that improve outcomes for patients.

By linking different clinical systems together into a seamless view of the patient, we can streamline patient pathways and deliver a digital health and diagnostics record across multiple care providers.

Bleepa® is our communication and collaboration platform that displays clinical results at a certified and regulated quality, which enables multi-disciplinary team working and diagnostic-enhanced advice and guidance. CareLocker® is our patient-facing platform that gives patients access and control over their diagnostic and other clinical data.

The Company has a number of growth opportunities domestically and internationally across a range of public and private healthcare markets including the NHS. Our highly scalable software-as-a-service (SaaS) based model is expected to provide increasing levels of revenue visibility as the Company grows its customer base.

Five reasons to invest in Feedback plc

 

  1. Aligned to key areas of NHS strategic priority, strong NHS contacts & large total addressable market (TAM).
  2. Strong position on intellectual property – Bleepa® is the only clinical communication platform UKCA marked for medical image display.
  3. Strong network of partners – well-positioned to capitalise on opportunities in the UK and abroad with a combined potential TAM of ‘£10bn’.
  4. Breadth of growth opportunities extends internationally across several markets, built on a highly scalable software-as-a-service model.
  5. Led by a team that brings together expertise from medical and specialist IT healthcare backgrounds.

~£10bn annual TAM estimated in core target markets

Estimated total address able market analysis – annual
1 2 3 4 5 6 TOTAL
NHS trusts NHS – CDCs Private hospitals (UK) Private hospitals (India) National TB screening ABDM (2) – health record
Geography UK UK UK India India India
Product(s) Bleepa® Bleepa® Bleepa® Bleepa® Bleepa®, Feedback Connect, CareLocker® CareLocker®
TAM £28m £96m £16m £1,020m £375m (1) £8,146m £9,681m

(1) Equivalent to an estimated total TAM of £1,875m across an estimated 5-year screening cycle for the population
(2) ABDM = The Ayushman Bharat Digital Mission, previously known as National Digital Health Mission (NDHM)

Factors driving change in the NHS

CDC initiative Cancer targets NHS operational planning guidance 2023 /2024 ICO NHS Lanarkshire ruling CDC requirement for tools & care record
  • National £2.3bn programme for multiple CDCs to drive faster diagnosis for patients
  • Growing need to connect CDCs to other care settings and streamline patient pathways > reduce wait times
  • Drive to meet the faster diagnosis standard – 75% of urgent referrals diagnosed or cancer ruled out within 28 days
  • Growing need to clearly identify cancer diagnosis standard breaches and improve patient care
  • £3bn of Elective Recovery Fund allocated to ICBs
  • Increase GP direct access
  • Deliver 2.2% efficiency targets and improve levels of productivity
  • Reprimand for NHS trust over clinician use of WhatsApp to share patient data
  • Growing need to implement safe, secure clinical communication tools within and across NHS organisations
  • Guidance for provision of appropriate staff tools and maintaining a contemporaneous care record
  • Regulator requirement for staff to have the right tools to do their job (including digital tools) and maintain a full, auditable record of patient care

Regulatory support

Data governance Medical device regulation Clinical risk
  • National £2.3bn programme for multiple CDCs to drive faster diagnosis for patients
  • Growing need to connect CDCs to other care settings and streamline patient pathways > reduce wait times
  • Drive to meet the faster diagnosis standard – 75% of urgent referrals diagnosed or cancer ruled out within 28 days
  • Growing need to clearly identify cancer diagnosis standard breaches and improve patient care
  • DCB 0129 – clinical risk and safety standard, risk analysis and mitigation for product design, manufacturing and operational processes
  • ISO 13485 certification demonstrating consistent quality of product releases

Explore more

Regulatory news (RNS)

Financial reports & presentations

Share information

AIM rule 26